Document Detail

How important is whole brain radiotherapy for treatment of primary CNS lymphoma?
MedLine Citation:
PMID:  20970379     Owner:  NLM     Status:  MEDLINE    
Fernando Cabanillas
Related Documents :
11707839 - Advances in the therapy of primary central nervous system lymphoma.
9816039 - Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given wit...
23608449 - Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two...
8608509 - Meningeal carcinomatosis in patients with breast carcinoma. clinical features, prognost...
23330999 - Distinct idh1/idh2 mutation profiles in purely insular versus paralimbic who grade ii g...
10102019 - Improvement in cns protective treatment in non-high-risk childhood acute lymphoblastic ...
16427859 - Does bilateral internal thoracic artery grafting increase long-term survival of diabeti...
9610709 - Final report of a phase ii evaluation of paclitaxel in patients with advanced squamous ...
9269159 - Idiopathic osteonecrosis of the medial femoral condyle. classification and treatment.
Publication Detail:
Type:  Comment; Letter     Date:  2010-10-20
Journal Detail:
Title:  The Lancet. Oncology     Volume:  11     ISSN:  1474-5488     ISO Abbreviation:  Lancet Oncol.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-05     Completed Date:  2010-12-07     Revised Date:  2014-08-18    
Medline Journal Info:
Nlm Unique ID:  100957246     Medline TA:  Lancet Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1011-2     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimetabolites, Antineoplastic / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Central Nervous System Neoplasms / drug therapy*,  mortality,  radiotherapy*
Cranial Irradiation* / adverse effects
Cytarabine / administration & dosage
Disease-Free Survival
Ifosfamide / administration & dosage
Lymphoma / drug therapy*,  mortality,  radiotherapy*
Methotrexate / administration & dosage
Radiotherapy, Adjuvant
Risk Assessment
Risk Factors
Survival Rate
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 04079A1RDZ/Cytarabine; UM20QQM95Y/Ifosfamide; YL5FZ2Y5U1/Methotrexate
Comment On:
Lancet Oncol. 2010 Nov;11(11):1036-47   [PMID:  20970380 ]
Comment In:
Lancet Oncol. 2011 Feb;12(2):118-9; author reply 119-20   [PMID:  21277546 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Presentation with pulsatile xiphisternal bruise-Survival with a chronic ventricular rupture.
Next Document:  High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG...